Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Therapeutic efficacy against cancer relies heavily on the ability of the therapeutic agents to reach their final targets. The optimal targets of most cancer therapeutic agents are usually biological macromolecules at the subcellular level, which play a key role in carcinogenesis. Therefore, to improve the therapeutic efficiency of drugs, researchers need to focus on delivering not only the therapeutic agents to the target tissues and cells but also the drugs to the relevant subcellular structures. In this review, we discuss the most recent construction strategies and release patterns of various cancer cell subcellular-targeting nanoformulations, aiming at providing guidance in the overall design of precise nanomedicine. Additionally, future challenges and potential perspectives are illustrated in the hope of enhancing anticancer efficacy and accelerating the translational progress of precise nanomedicine.

Related collections

Most cited references 151

Record: found
Abstract: found
Article: found

Is Open Access

Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness

Michiru Nishita, Seung-Yeol Park, Tadashi Nishio … (2017)

Signaling through the Ror2 receptor tyrosine kinase promotes invadopodia formation for tumor invasion. Here, we identify intraflagellar transport 20 (IFT20) as a new target of this signaling in tumors that lack primary cilia, and find that IFT20 mediates the ability of Ror2 signaling to induce the invasiveness of these tumors. We also find that IFT20 regulates the nucleation of Golgi-derived microtubules by affecting the GM130-AKAP450 complex, which promotes Golgi ribbon formation in achieving polarized secretion for cell migration and invasion. Furthermore, IFT20 promotes the efficiency of transport through the Golgi complex. These findings shed new insights into how Ror2 signaling promotes tumor invasiveness, and also advance the understanding of how Golgi structure and transport can be regulated.

0 comments Cited 3373 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

Lorenzo Galluzzi, Ilio Vitale, Stuart A. Aaronson … (2018)

Over the past decade, the Nomenclature Committee on Cell Death (NCCD) has formulated guidelines for the definition and interpretation of cell death from morphological, biochemical, and functional perspectives. Since the field continues to expand and novel mechanisms that orchestrate multiple cell death pathways are unveiled, we propose an updated classification of cell death subroutines focusing on mechanistic and essential (as opposed to correlative and dispensable) aspects of the process. As we provide molecularly oriented definitions of terms including intrinsic apoptosis, extrinsic apoptosis, mitochondrial permeability transition (MPT)-driven necrosis, necroptosis, ferroptosis, pyroptosis, parthanatos, entotic cell death, NETotic cell death, lysosome-dependent cell death, autophagy-dependent cell death, immunogenic cell death, cellular senescence, and mitotic catastrophe, we discuss the utility of neologisms that refer to highly specialized instances of these processes. The mission of the NCCD is to provide a widely accepted nomenclature on cell death in support of the continued development of the field.

0 comments Cited 1951 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Cancer nanomedicine: progress, challenges and opportunities

Jinjun Shi, Philip Kantoff, Richard Wooster … (2016)

The intrinsic limits of conventional cancer therapies prompted the development and application of various nanotechnologies for more effective and safer cancer treatment, herein referred to as cancer nanomedicine. Considerable technological success has been achieved in this field, but the main obstacles to nanomedicine becoming a

0 comments Cited 1121 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Guimei Lin: guimeilin@sdu.edu.cn

Journal

Journal ID (nlm-ta): Signal Transduct Target Ther

Journal ID (iso-abbrev): Signal Transduct Target Ther

Title: Signal Transduction and Targeted Therapy

Publisher: Nature Publishing Group UK (London )

ISSN (Print): 2095-9907

ISSN (Electronic): 2059-3635

Publication date (Electronic): 6 November 2020

Publication date PMC-release: 6 November 2020

Publication date Collection: 2020

Volume: 5

Electronic Location Identifier: 262

Affiliations

[1 ]GRID grid.27255.37, ISNI 0000 0004 1761 1174, Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, , Shandong University, ; Jinan, 250012 Shandong China

[2 ]GRID grid.443420.5, ISNI 0000 0000 9755 8940, School of Mechanical and Automotive Engineering, , Qilu University of Technology (Shandong Academy of Sciences), ; Jinan, 250353 Shandong China

[3 ]GRID grid.27255.37, ISNI 0000 0004 1761 1174, The Second Hospital, Cheeloo College of Medicine, , Shandong University, ; Jinan, 250033 Shandong China

Article

Publisher ID: 342

DOI: 10.1038/s41392-020-00342-0

PMC ID: 7644763

PubMed ID: 33154350

SO-VID: 07d79d2c-3d47-4140-aad2-fe2bb6840756

License:

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

History

Date received : 29 June 2020

Date revision received : 26 August 2020

Date accepted : 14 September 2020

Funding

Funded by: FundRef https://doi.org/10.13039/501100001809, National Natural Science Foundation of China (National Science Foundation of China);

Award ID: 21873057

Award Recipient : Guimei Lin

Funded by: FundRef https://doi.org/10.13039/501100007129, Natural Science Foundation of Shandong Province (Shandong Provincial Natural Science Foundation);

Award ID: ZR2019MB041

Award Recipient : Guimei Lin

Funded by: the Fundamental Research Funds of Shandong University (Grant No. 2018JC006)

Funded by: the Major Basic Research Project of Shandong Natural Science Foundation, P. R. China (Grant No. ZR2018ZC0232)

Custom metadata

Keywords: drug delivery,drug development

Data availability:

Keywords: drug delivery, drug development

Comments

Comment on this article

scite_

Cited by 33

See all cited by

Most referenced authors 13,033

See all reference authors

Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting

Read this article at

Abstract

Related collections

RNA drug delivery

Most cited references 151

Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

Cancer nanomedicine: progress, challenges and opportunities

Author and article information

Contributors

Journal

Affiliations

Article

History

Funding

Categories

Custom metadata

Comments

Comment on this article

Similar content 384

Cited by 33

Most referenced authors 13,033